alexa Improvement of Motor, Sensory, and Functional Status of Post-Guillain-Barre Syndrome with the Use of 4-Aminopyridine
ISSN: 2329-9096

International Journal of Physical Medicine & Rehabilitation
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Improvement of Motor, Sensory, and Functional Status of Post-Guillain-Barre Syndrome with the Use of 4-Aminopyridine

Jay M. Meythaler1* and Robert C. Brunner2

1 Department of Physical Medicine and Rehabilitation-Oakwood, Wayne State University School of Medicine

2 Department of Physical Medicine & Rehabilitation University of Alabama School of Medicine

*Corresponding Author:
Jay M. Meythaler
Professor-Chair, Dept. Physical Medicine and Rehabilitation-Oakwood
Wayne State University School of Medicine
18181 Oakwood BLVD, Suite 411
Dearborn, MI 48124, USA
Tel: (313)438-7373
Fax: (313)438-7375
E-mail: [email protected]

Received Date: February 15 2014; Accepted Date: May 20 2014; Published Date: May 23 2014

Citation: Meythaler JM and Brunner RC (2014) Improvement of Motor, Sensory, and Functional Status of Post-Guillain-Barre Syndrome with the Use of 4-Aminopyridine. Int J Phys Med Rehabil 2:202. doi: 10.4172/2329-9096.1000202

Copyright: © 2014 Meythaler JM et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine for motor weakness due to Guillain-Barre Syndrome (GBS) under a FDA approved protocol (IND No: 58,029). Setting: Tertiary care outpatient and inpatient rehabilitation center directly attached to a university hospital. Subjects: Seven subjects who were unable to ambulate more than 200 feet without assistive devices and had residual nonprogressive motor weakness due to GBS more than one year out from the initial episode. Design: Subjects were randomized to a double-blind, placebo-controlled, cross-over design, which had two fourweek treatment arms with a one-week washout. The average dosage at 4 weeks was 30 milligrams (mg) per day. Data set: Data for motor strength utilizing a traditional 5 point motor scale and handgrip strength were evaluated. Differences over times were assessed via descriptive statistics, Friedman’s analysis, Wilcoxon signed-rank, ANOVA and paired Student’s t-test. Subjects were evaluated for dose and side effects as required by our FDA approved protocol (IND No: 58,029). Results: During four weeks of treatment, the averaged lower extremity (LE) motor strength increased from 3.2 SD ± 1.2 to 3.7 SD ± 1.0 (p<0.0001), the average upper extremity (UE) motor strength increased from 3.2 SD ± 1.2 to a maximum of 4.3 SD ± 0.9 (p=0.0073) and the grip strength bilaterally increased from 8.2 lbs. SD+ 9.1 lbs. to 12.2 lbs. SD ± 9.1 lbs. (p=0.0243). There were no statistical changes in the placebo arm regarding LE and UE motor strength or the grip strength at week 4 (p>0.05). Only three laboratory tests had a statistically significant change as the uric acid changed from 6.4 to 6.5, the SGOT went up from 25.1 to 27.9 and the hematocrit dropped from 42.7 to 41.6. None of these results were deemed to be clinically relevant changes. There were no seizures and there was no significant change in the Q – T interval in any of the subjects. Three subjects did report increased paresthesias on 4-aminopyridine. Conclusion: This Phase IIa trial indicates 4-aminopyridine was generally safe and may be effective in improving the motor function of GBS subjects. Further research requires delineating its biologic half-life, which appears to be longer than two weeks.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version